. 2015 Oct 13;10(10):e0140222. doi: 10.1371/journal.pone.0140222

Table 4. Association of FGF-23 with aPWV in the patients with T1DM.

	B	SD	β	95%CI	p
Model 1 (age, sex, eGFR and classical cardiovascular risk factors) (R² = 0.529; p<0.001)
Age	0.049	0.014	0.328	0.021–0.079	0.001
BMI	0.180	0.038	0.427	0.104–0.257	<0.001
FGF-23	0.002	0.001	0.202	0.001–0.003	0.026
Hypertension (N/Y)	0.738	0.366	0.192	0.007–1.469	0.048
Model 2 (model 1 + mineral metabolism) (R² = 0.580; p<0.001)
Age	0.043	0.014	0.282	0.015–0.071	0.004
BMI	0.183	0.037	0.432	0.109–0.257	<0.001
FGF-23	0.02	0.001	0.214	0.001–0.003	0.015
25(OH)D	-0.011	0.005	-0.234	-0.020–-0.002	0.018
Hypertension(N/Y)	0.771	0.351	0.200	0.069–1.473	0.032
Model 3 (model 2 + duration and microvascular complications + inflammation and ED) (R² = 0.587; p<0.001)
Age	0.054	0.013	0.353	0.027–0.080	<0.001
BMI	0.182	0.037	0.431	0.109–0.255	<0.001
Microvascular complications (N/Y)	0.783	0.319	0.203	0.144–1.422	0.017
FGF-23	0.001	0.002	0.170	0.001–0.003	0.045
25(OH)D	-0.011	0.005	-0.241	-0.020–-0.002	0.015

Model 1 adjusted for age, sex, eGFR, current smoking (No/Yes), arterial hypertension (No/Yes), dyslipidaemia (No/Yes), BMI and FGF-23. Model 2 adjusted for covariates in model 1 and variables reflecting mineral metabolism (calcium, phosphate, PTH and 25(OH)D). Model 3 adjusted for covariates in model 2 and duration of diabetes (years) and the presence of microvascular complications (diabetic retinopathy, nephropathy and peripheral polyneuropathy) and low-grade inflammation general score and endothelial dysfunction score. 25(OH)D were additionally adjusted for seasonality.